SSY Group (HKG:2005) obtained registration approval for Azilsartan Medoxomil Potassium to become a bulk drug for the preparations on the market from China's National Medical Products Administration.
The drug is used to treat primary hypertension in adults, according to a Thursday filing by the pharmaceutical firm with the Hong Kong bourse.